Key Points
- OrbiMed Advisors sold 48,546 Sionna Therapeutics shares on May 7 at an average price of $44.61, and later disclosed additional sales on May 8 and May 11. The combined transactions were made under a pre-arranged Rule 10b5-1 plan.
- Sionna Therapeutics shares were trading near $45.95, close to the stock’s 52-week high of $48.45, with a market cap of about $2.07 billion. The stock has also outperformed its 50-day and 200-day moving averages.
- Analysts remain generally upbeat, with a Moderate Buy consensus and an average price target of $53.00. The company recently beat quarterly EPS estimates, reporting a loss of ($0.46) versus expectations of ($0.61).
Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Orbimed Advisors Llc sold 48,546 shares of the firm's stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $44.61, for a total value of $2,165,637.06. Following the sale, the director directly owned 2,916,228 shares of the company's stock, valued at $130,092,931.08. This represents a 1.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Orbimed Advisors Llc also recently made the following trade(s):
- On Monday, May 11th, Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58.
- On Friday, May 8th, Orbimed Advisors Llc sold 59,767 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total value of $2,664,412.86.
- On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.52, for a total value of $131,244.96.
- On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.68, for a total value of $2,341,097.96.
- On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total value of $10,287,918.04.
- On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total value of $10,528,924.32.
- On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.51, for a total value of $2,128,201.14.
Sionna Therapeutics Stock Performance
Shares of Sionna Therapeutics stock opened at $45.95 on Tuesday. Sionna Therapeutics, Inc. has a 52 week low of $11.77 and a 52 week high of $48.45. The stock has a 50 day moving average price of $38.84 and a two-hundred day moving average price of $39.47. The stock has a market capitalization of $2.07 billion, a PE ratio of -23.56 and a beta of 1.35.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.15. Research analysts forecast that Sionna Therapeutics, Inc. will post -2.32 EPS for the current year.
Analysts Set New Price Targets
A number of equities research analysts have commented on the company. UBS Group reissued a "buy" rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Lifesci Capital raised Sionna Therapeutics to a "strong-buy" rating in a research note on Wednesday, February 25th. Wedbush assumed coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They issued an "outperform" rating and a $53.00 price objective for the company. BTIG Research reissued a "buy" rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a research note on Monday, April 27th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Sionna Therapeutics in a research note on Friday. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Sionna Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $53.00.
Read Our Latest Stock Analysis on Sionna Therapeutics
Institutional Trading of Sionna Therapeutics
A number of hedge funds have recently bought and sold shares of SION. Goldman Sachs Group Inc. bought a new stake in Sionna Therapeutics during the first quarter worth $667,000. Woodline Partners LP bought a new stake in Sionna Therapeutics during the first quarter worth $837,000. Geode Capital Management LLC lifted its holdings in Sionna Therapeutics by 113.4% during the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company's stock worth $5,020,000 after acquiring an additional 153,712 shares during the period. Rhumbline Advisers bought a new stake in Sionna Therapeutics during the second quarter worth $307,000. Finally, New York State Common Retirement Fund bought a new stake in Sionna Therapeutics during the second quarter worth $118,000.
Sionna Therapeutics News Summary
Here are the key news stories impacting Sionna Therapeutics this week:
- Negative Sentiment: Director Peter A. Thompson, through OrbiMed Advisors, sold a combined 292,952 shares over May 7, May 8, and May 11 at prices between $44.58 and $46.22. While the sales were made under a pre-arranged Rule 10b5-1 plan, the size and timing of the transactions can still weigh on sentiment because they suggest insiders are monetizing shares after a strong run. Article Title
- Neutral Sentiment: The company’s short-interest report showed 0 shares short as of May 11, indicating no meaningful bearish positioning data from that filing. By itself, this does not materially change the investment outlook, but it does suggest there is not an obvious short-seller overhang in the reported data. Article Title
About Sionna Therapeutics
(
Get Free Report)
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
